Figure 2.
Molecular design and coagulation studies: (A) PARIN5 is based on sequence homology with PAR1, which makes it recognized by thrombin. The molecule was modified with a tosyl group as a protective group at the N-terminal, and with chloro-methyl-ketone (CMK) as a serine active site blocker at the C-terminal. Coagulation studies (B–D) were conducted to identify the optimal therapeutic window for PARIN5 treatment. Orange arrows correspond to treatment dosages.
